VC Community is Gearing up for BIO-Europe Spring® 2013

  VC Community is Gearing up for BIO-Europe Spring® 2013

           Investors will be a strong presence at partnering event

BIO-Europe Spring 2013

Business Wire

ZURICH & BARCELONA, Spain -- February 20, 2013

The seventh annual BIO-Europe Spring® international partnering conference will
be held at the CCIB Convention Centre Barcelona in Barcelona, Spain, March
11–13, 2013. High attendance by pharma and biotech investors and venture
capital firms is expected at the event, which will draw more than 2,000
executive-level attendees from over 1,300 companies.

“Over recent years, the role of VCs has really changed,” said Carola Schropp,
President of EBD Group. “At BIO-Europe Spring, many of the funds that still
invest early will be present. There will be several workshops where investors
will sit down with pharma to discuss collaborative approaches to financing
early stage biotechs. This goes to show that both pharma and venture have
taken on new roles in driving innovation.”

One highlight of the program is the Monday morning, March 11, workshop
entitled “Exploring alternative financing models,” moderated by Steve Dickman,
CEO of CBT Advisors, and featuring panelists from VC firms including Sinclair
Dunlop, Managing Partner of Rock Spring Ventures; Joël Jean-Mairet, General
Partner of Ysios Capital; Kevin Johnson, Partner of Index Ventures; as well as
Melissa Stevens, Deputy Executive Director of FasterCures.

The workshop will highlight issues related to the shortage of traditional VC
investments and the growing prevalence of creative financing models for early
stage and pre-IPO start-ups. The workshop is expected to foster an engaging
discussion on these new investment approaches and what is driving this trend
in the market.

“These days there is a lot of interest in early stage investing,” said Joël
Jean-Mairet, Managing Partner at Ysios Capital, a Barcelona-based firm.
“Investors are eager to tap into new drug development candidates earlier on
provided that these are highly disruptive, and there are a lot of creative
financing models developing in the field to capitalize on this early
innovation while keeping the investments lucrative. I think the panel at
BIO-Europe Spring will be extremely informative to both investors and

“There is a significant amount of untapped discovery out there, and many high
potential young companies require capital to achieve critical milestones in
the discovery process,” said Sinclair Dunlop of Rock Spring Ventures. “Current
investment models are failing to deploy sufficient early stage capital to
these types of high growth companies.”

Sander Slootweg, Managing Partner of Forbion Capital Partners, will moderate a
panel called “Going public: A review of 2012's IPOs” with panelists Barbara
Duncan, CFO of Intercept Pharmaceuticals; Dan Dubin, Managing Director and
Vice Chairman of Leerink Swann; C.A. (Oscar) Izeboud, Managing Director of
Kempen & Co Corporate Finance B.V.; and Daniel Paterson, VP and Head,
Corporate Development and Diagnostics of Verastem.

"One main topic we are going to explore on the panel is the differences
between the EU and the US markets for IPOs and, more broadly, the capital
markets and how we can potentially improve the functioning of the capital
markets in Europe. This is certainly of interest to potential investors, and
is part and parcel of what BIO-Europe Spring is about," said Slootweg.

“The choices we make need to be the right ones for years to come. Addressing
real medical needs is what drives our strategy and brings us with a higher
probability to the right programs. Then it requires quality analysis to
identify the best people and the best science. BIO-Europe Spring is an
excellent place to get in touch with potential right partners,” said Olivier
Litzka with Edmond de Rothschild Investment Partners. Since 2005, Rothschild
has supported 25 European biotech and medtech companies, and, while now at EUR
170 million raised, is planning the closing of its EUR 200 million
BioDiscovery4 fund in late spring. Litzka is on a panel called “Therapeutic
Insight: Antibiotics.”

The Host Committee for BIO-Europe Spring 2013 in Barcelona is coordinated by
Biocat and the Barcelona City Council—through Barcelona Activa—and receives
support from other sector organizations and companies from the BioRegion of
Catalonia, including Almirall, Amgen, Biokit, Reig Jofré and Ysios Capital.

The 2012 edition was held in Amsterdam, The Netherlands, and welcomed 2,157
delegates representing 1,304 companies vying for an estimated 2,508 licensing
opportunities. 11,172 one-to-one meetings took place at that event among
companies across the life science value chain, from large biotech and pharma
companies to financiers and innovative start-ups.

One-to-one partnering meetings for the 2013 edition in Barcelona can be
requested utilizing partneringONE®. To be included in the first round of
scheduling, request your meetings by March 1.

As the leading conference networking solution for the life sciences, the
system generates over 40,000 one-to-one meetings annually at EBD Group's six
life science partnering events held around the world. With partneringONE,
pharma and biotech dealmakers can create a partnering profile and begin
efficiently identifying and requesting meetings with potential collaborators.
For more about partneringONE and how to log on to your account, go to

Information for BIO-Europe Spring can be found online at

Follow EBD Group on Twitter: (Hashtag #BES13).

Notes to Editors:

Entry to BIO-Europe Spring 2013 is free to members of the press, including
full access to the partnering system, sessions, press conferences, workshops,
and pre-arranged partnering meetings. Visit the BIO-Europe Spring conference
website at for registration details.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry.
Since 1993, biotech, pharma and medical device companies have leveraged EBD
Group’s partnering conferences, technology and services to identify business
opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and
international trade associations and include:

  *BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science
    partnering conferences, supported by the Biotechnology Industry
    Organization (BIO)
  *BioPharm America™, the fastest growing partnering event in North America
  *Biotech Showcase™, a unique forum in San Francisco for presenting to
    investors and business development executives, co-produced with
    Demy-Colton Life Science Advisors
  *BioEquity Europe, the investor conference co-organized with BioCentury
    Publications and BIO
  *ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering
    conference in China, co-produced with ChinaBio® LLC
  *EuroMedtech™, EBD Group’s partnering event for the innovative medical
    technology industry
  *Partnering for Global Impact®, a new partnering conference providing an
    innovative forum to partner, identify and generate social and
    philanthropic investment and funding opportunities

EBD Group’s sophisticated web-based partnering service, partneringONE®, is
also used as the partnering engine at numerous third-party events around the
world, and partnering360® is the open online community of life science
dealmakers that enhances partnering experiences all year long.

Outside of the conference format, EBD Group’s consultants provide hands-on
assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit

Photos/Multimedia Gallery Available:



EBD Group
Erin Righetti, +1-760-930-0500
Press spacebar to pause and continue. Press esc to stop.